X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/amgen-presents-new-research-on-otezla-apremilast-at-aad-2024-302084594.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211734
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217258
https://www.prnewswire.com/news-releases/skyrizi-risankizumab-achieved-superiority-versus-apremilast-for-co-primary-endpoints-among-adult-patients-with-moderate-plaque-psoriasis-in-phase-4-head-to-head-study-301885778.html
https://www.prnewswire.com/news-releases/amgen-wins-patent-appeal-on-otezla-apremilast-301802357.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211774
https://tiefenbachergroup.com/2022/12/01/new-market-launch-tiefenbacher-pharmaceuticals-successfully-launches-generic-version-of-the-psoriasis-medication-apremilast-in-canada/
https://www.prnewswire.com/news-releases/amgen-announces-positive-new-data-at-eadv-2022-for-otezla-apremilast-301619822.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211897
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211859
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211859
https://www.expresspharma.in/us-fda-approves-expanded-use-of-amgens-psoriasis-drug/
https://www.prnewswire.com/news-releases/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level-301448542.html
https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level
https://www.expresspharma.in/amgen-announces-positive-top-line-results-from-otezla-phase-iii-discreet-study-in-moderate-to-severe-genital-psoriasis/
https://www.pmlive.com/pharma_news/bms_new_jak_inhibitor_enters_regulatory_pathways_1384682
https://www.prnewswire.com/news-releases/amgen-announces-positive-top-line-results-from-otezla-apremilast-phase-3-discreet-study-in-moderate-to-severe-genital-psoriasis-301435620.html
https://www.fiercepharma.com/pharma/amgen-scores-otezla-patent-win-protecting-its-blockbuster-against-sandoz-and-zydus-copycats
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211859
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211761
https://www.prnewswire.com/news-releases/amgen-wins-patent-case-on-otezla-apremilast-301380921.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211782
https://www.prnewswire.com/news-releases/fda-accepts-amgens-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis-301283931.html
https://www.pharmiweb.com/press-release/2021-05-06/fda-accepts-amgens-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis
https://www.fiercepharma.com/pharma/a-rough-earnings-report-for-amgen-reflects-increased-competition-and-pricing-stress
https://www.prnewswire.com/news-releases/otezla-apremilast-significantly-improved-measures-of-disease-severity-in-adults-with-mild-to-moderate-plaque-psoriasis-301276001.html
https://www.fiercebiotech.com/biotech/bristol-myers-deucravacitinib-beats-out-exiled-otezla-eyes-2022-launch
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/shilpa-medicare-gets-tentative-american-health-regulator-nod-for-apremilast-tablets/articleshow/81344008.cms
https://endpts.com/amgen-lines-up-expansion-to-otezlas-13b-franchise-china-oks-breakthrough-use-of-pd-1/
https://www.prnewswire.com/news-releases/amgen-submits-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis-301231965.html
https://www.prnewswire.com/news-releases/amgen-submits-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis-301231965.html
https://www.thehindubusinessline.com/companies/unichem-labs-zooms-6-on-usfda-approval-for-apremilast-tablets/article33878588.ece
https://www.fiercepharma.com/marketing/moderna-jump-starts-commercial-team-cco-hire-as-it-rolls-out-its-covid-19-vaccine
https://endpts.com/amgen-hands-off-licensing-rights-to-leprosy-tuberculosis-med-picked-up-as-part-of-13-4b-otezla-deal/
https://endpts.com/bristol-myers-posts-another-win-for-their-otezla-competitor-this-time-with-phii-data-in-psoriatic-arthritis/
https://www.fiercepharma.com/pharma/abbvie-s-skyrizi-stands-to-gain-from-physicians-move-away-from-older-meds-like-amgen-s
https://www.fiercepharma.com/pharma/abbvie-amgen-and-takeda-test-anti-inflammatory-drugs-joint-covid-19-study
https://www.biopharmadive.com/news/covid-platform-trial-amgen-abbvie-takeda/582796/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211887
https://www.fiercepharma.com/pharma/amgen-s-otezla-helps-drive-growth-despite-covid-19
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211658
https://www.prnewswire.com/news-releases/amgen-is-supporting-advancement-of-amg-634-for-global-health-diseases-in-developing-countries-301081303.html
https://www.amgen.com/media/news-releases/2020/06/amgen-is-supporting-advancement-of-amg-634-for-global-health-diseases-in-developing-countries/
https://www.prnewswire.com/news-releases/amgen-announces-positive-top-line-results-from-otezla-apremilast-phase-3-advance-study-in-mild-to-moderate-plaque-psoriasis-301053621.html
http://www.pmlive.com/pharma_news/amgen_adds_otezla_to_the_covid-19_candidate_list_1339599
https://www.raps.org/news-and-articles/news-articles/2020/2/chmp-recommends-one-new-drug-begins-review-of-ind
https://www.fiercepharma.com/pharma/copycats-weighed-amgen-2019-but-company-says-new-launches-biosims-and-otezla-will-drive
https://www.fiercepharma.com/pharma/after-ftc-surprises-what-antitrust-scrutiny-should-biopharma-expect-their-m-a-deals-2020
Market Place
Share 
